Welcome to our dedicated page for High Tide SEC filings (Ticker: HITI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The High Tide Inc. (HITI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer with securities listed in the United States. High Tide files its annual disclosure on Form 40-F and furnishes current information on Form 6-K under the Securities Exchange Act of 1934.
Recent Form 6-K filings for High Tide have attached company news releases as exhibits. These filings cover topics such as new Canna Cabana store openings in Canadian provinces, the launch of an international Canna Cabana location in Berlin, participation in investor conferences, and recognition in external business rankings. Some 6-Ks also reference material change reports and other corporate updates that the company furnishes to U.S. investors.
For those analyzing HITI, these SEC filings help document how High Tide communicates its strategy, expansion plans, and operational milestones to the market. They complement the company’s Canadian disclosure on SEDAR+ and provide a U.S. regulatory record of its news releases and material changes. Because High Tide operates across cannabis retail, e-commerce, and German medical cannabis distribution, its filings can touch on developments in each of these areas.
On Stock Titan, users can view High Tide’s latest 6-K submissions as they are made available through EDGAR. The platform associates each filing with AI-powered tools that can assist in understanding the contents and context of the documents, helping readers navigate the company’s ongoing regulatory communications more efficiently.
High Tide Inc. filed an amended statement of executive compensation for the year ended October 31, 2025, correcting omissions and errors in its prior disclosure and updating finalized annual incentive payouts.
The filing details the company’s pay philosophy, use of a cannabis‑sector peer group, and a three-part program of salary, discretionary cash bonuses, and long-term equity under a 20% fixed Omnibus Plan. In 2025, CEO Harkirat (Raj) Grover received salary of $825,000, a bonus of $1,056,000 and share-based awards of $1,540,111, for total compensation of $3,382,845. Across executives and directors, 708,164 RSUs were granted, and outstanding options and RSUs feature broad change-of-control vesting and severance protections.
High Tide Inc. is responding to investor concerns about unusual trading in its common shares. The company says it has observed, over more than ten consecutive quarters, that its strong earnings results often spark positive after-hours reactions, yet the next regular-session closing price frequently falls below the prior close.
Management and the board, working with the company’s market maker, have been reviewing trading data and now believe some activity may not reflect normal market forces and may be contrary to securities laws. High Tide plans to hire forensic investigators and trading‑surveillance specialists to review trading around earnings and other material news, and expects to share their findings with Canadian and U.S. regulators.
The company invites shareholders and market participants with relevant information to contact its investor relations team. High Tide highlights its cannabis retail and medical operations, including 221 Canna Cabana locations and a 12% share of the Canadian market, along with its German medical cannabis distributor Remexian Pharma.
High Tide Inc. filed a Form 6-K highlighting the opening of a new Canna Cabana retail cannabis store in Caledonia, Ontario. The store at 345 Argyle Street South began selling recreational cannabis and accessories for adult use on April 20, 2026, bringing the Canna Cabana network to 221 locations across Canada, including 97 in Ontario.
The Caledonia store is located at the south end of town in a busy commercial node alongside a pharmacy, liquor store, and national retailers, targeting a growing trade area with strong household incomes. CEO Raj Grover framed the 4/20 opening as a symbolic milestone as the brand approaches eight years since its first Canna Cabana store, positioning the launch as part of a disciplined national scaling strategy.
High Tide Inc. filed a Form 6-K announcing that its senior executives and advisors will speak on panels at multiple cannabis and investor conferences across North America and Europe from April to June 2026.
The company describes itself as a leading retail-forward cannabis enterprise, with its Canna Cabana chain operating 220 Canadian stores and 1 international location and holding a 12% share of the Canadian market. Its German subsidiary, Remexian Pharma GmbH, is licensed to import medical cannabis from 19 countries.
High Tide Inc. reports that its U.S. hemp-derived CBD subsidiary, NuLeaf Naturals, is pursuing participation in the U.S. Centers for Medicare & Medicaid Services Innovation Center’s Beneficiary Engagement Incentive pilot program. The pilot, launching April 1, 2026, allows certain Medicare model participants to furnish eligible hemp-derived CBD products to beneficiaries at no cost, up to US$500 per year per beneficiary, with costs borne by participating organizations.
NuLeaf Naturals, founded in 2014 and operating cGMP-certified, FDA-registered facilities, believes its THC-free and broad-spectrum CBD products align with the program’s compliance requirements. High Tide views this pilot as a potential growth driver for its U.S. CBD business while continuing advocacy through the National Compassionate Care Council.
High Tide Inc. reported strong first fiscal quarter 2026 results, with revenue of $178,329 thousand, up 25% from $142,461 thousand a year earlier. Gross profit also rose 25% to $44,409 thousand, keeping gross margin steady at 25%, showing the business is growing while maintaining pricing and cost discipline.
Adjusted EBITDA improved to $11,457 thousand, a 62% increase from $7,089 thousand, and Adjusted EBITDA margin edged up to 6%. Net loss narrowed significantly to $352 thousand from $2,689 thousand, and basic and diluted income (loss) per share improved to $0.01 from $(0.03).
Cash generation improved meaningfully. Net cash provided by operating activities was $5,860 thousand versus $683 thousand, and free cash flow swung to a positive $2,939 thousand from negative $1,900 thousand. Management highlighted record revenue exceeding $700 million annualized, continued expansion of Canna Cabana’s 220-store Canadian network, growing German medical cannabis sales through Remexian, and recovering U.S. e-commerce trends.
High Tide Inc. reported much stronger results for the quarter ended January 31, 2026. Revenue rose 25% to $178.3M, driven mainly by Canadian bricks-and-mortar sales of $149.7M and medical cannabis distribution revenue of $25.0M from Remexian in Germany.
Gross profit increased 25% to $44.4M, maintaining a 25% gross margin. Income from operations improved to $2.4M from $0.1M, while the net loss narrowed to $0.4M. Adjusted EBITDA grew 62% to $11.5M, and free cash flow swung to a positive $2.9M from a $1.9M outflow.
The company ended the quarter with total assets of $346.4M, shareholders’ equity of $102.0M, and cash and restricted cash of $46.4M. High Tide operated 218 Canadian retail stores as of January 31, 2026 and highlighted rapid growth in its Cabana Club and Elite loyalty programs.
High Tide Inc. filed a report highlighting the opening of its 220th Canna Cabana cannabis store, located on London Road in Sarnia, Ontario, which will start selling adult-use products on March 9, 2026. This is the Company’s first store in Sarnia and its 96th location in Ontario.
High Tide also announced it will release financial and operational results for the quarter ended January 31, 2026 after markets close on March 17, 2026, followed by a webcast on March 18, 2026 with its CEO and CFO to discuss the results and outlook.
High Tide Inc. filed a Form 6-K highlighting that it and its U.S. hemp-derived CBD subsidiary NuLeaf Naturals have joined the U.S. National Compassionate Care Council as founding members. The Council focuses on improving patient access to cannabinoid therapies through modernized, evidence-based healthcare standards.
Management notes that recent U.S. federal initiatives to reschedule cannabis and explore Medicare reimbursement for hemp-derived cannabinoid products could materially affect High Tide’s American CBD operations. The filing also profiles High Tide’s broader business, including its 219-location Canna Cabana retail chain with a 12% Canadian market share and its German medical cannabis distributor Remexian Pharma.
High Tide Inc. reported board and leadership changes alongside new equity awards. Two long-serving directors, Nitin Kaushal and Andrea Elliott, resigned effective March 2, 2026, and were replaced by Kathleen Skerrett, a securities and governance lawyer, and technology entrepreneur Menashe Kestenbaum.
The company also added David Wallach and Filip Ernest to its Advisory Board to guide real estate, business development, artificial intelligence, e-commerce and stakeholder initiatives. To align incentives, High Tide granted 123,558 restricted stock units and 25,000 stock options, each option exercisable at $3.43 per share for three years, under its omnibus equity plan and subject to statutory holding periods.